 |
Photo = Yonhap news |
[Alpha Biz= Paul Lee] Samsung Biologics announced on June 10 that it has signed a contract manufacturing organization (CMO) agreement worth $75.39 million (KRW 102.45 billion) with a European-based pharmaceutical company.
The deal represents approximately 2.25% of Samsung Biologics' 2024 annual revenue of KRW 4.55 trillion. The contract will be in effect from today until December 31, 2031.
Due to confidentiality reasons, the identity of the contracting party will be disclosed on December 31, 2031, although this date is subject to change.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
